As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Pharmacokinetic / pharmacodynamics (PK/PD) modeling, an integral component of the drug development process, is a mathematical technique for predicting the effect and efficacy of drug dosing over time. Broadly speaking, pharmacokinetic models describe how the body reacts to a drug in terms of absorption, distribution, metabolism, and excretion. Pharmacodynamic models describe how a drug affects the body by linking the drug concentration to an efficacy (or safety) metric. A well-characterized PK/PD model is an important tool in guiding the design of future experiments and trials.
• Development of PK/PD strategy as part of the drug development plan
• Design of standalone Pharmacokinetic(PK) studies and sub-studies
• Sample size and power calculations
• Generation of randomization codes
• Preparation of analysis plans
• Compartmental and non-compartmental pharmacokinetic analysis
• Pharmacodynamic analysis
• Assessment of PK/PD relationship
• Assessment of Bioequivalence/Bioavailability
• Drug interaction evaluations
• Reporting
• PK = Pharmacokinetics
– relationship between the dose administered and the changes in the drug concentration in the body with time. (Measured by drug concentration in blood, plasma, tissue)
– ADME
» Absorption
» Distribution
» Metabolism
» Elimination
• PD = Pharmacodynamics
– relationship between drug concentration and its pharmacologic effect (Effects of a drug on the body / disease)
PK is a determinant of PD
Pharmacokinetics is the study of what the body does to the drug.Pharmacodynamics is the study of what the drug does to the body.
• Pharmacodynamic Parameters
• Dose-Response Relationships
• Therapeutic Index
• Dose–Response Relationship
» The numbers of receptors
» The willingness of a drug to associate with a receptor = receptor affinity
» The presence of other compounds competing for the binding site on the receptor = agonist /antagonist
» The concentration of the free drug in the vicinity of the receptor = pharmacokinetics
Therapeutic Index
The therapeutic index (also known as therapeutic ratio), is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes death (in animal studies) or toxicity (in human studies).
PK-PD Changes in Critical Illness
» Circulatory Failure
» Hepatic Failure
» Renal Failure
» Systemic Inflammatory Response Syndrome
» Changes in Receptors in Acute Illness
» Protein Binding
Related Articles:
Preclinical Pharmacokinetic Study Service
Drug Metabolism and Pharmacokinetics (DMPK) Studies
Medicilon’s Preclinical Pharmacokinetic Study Services
Medicilon’s Drug ADME/PK Assays Services